Home
/
Relay Therapeutics, Inc.
/
Financials
/
Quarterly
Relay Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Relay Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 6, 2025
Q2
2025
Jun 30, 2025
$677.0K
Aug 7, 2025
Q1
2025
Mar 31, 2025
$7.68M
May 5, 2025
Q3
2025
Sep 30, 2024
$0
Nov 6, 2025
Q2
2025
Jun 30, 2024
$0
Aug 7, 2025
Q1
2025
Mar 31, 2024
$10.01M
May 5, 2025
Q3
2024
Sep 30, 2023
$25.20M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$119.0K
Aug 6, 2024
Q1
2024
Mar 31, 2023
$226.0K
May 2, 2024
Q3
2023
Sep 30, 2022
$344.0K
Nov 2, 2023
Q2
2023
Jun 30, 2022
$365.0K
Aug 8, 2023
Q1
2023
Mar 31, 2022
$419.0K
May 4, 2023
Q3
2022
Sep 30, 2021
$666.0K
Nov 3, 2022
Q2
2022
Jun 30, 2021
$844.0K
Aug 4, 2022
Q1
2022
Mar 31, 2021
$952.0K
May 5, 2022
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 6, 2025
Q2
2025
Jun 30, 2025
$677.0K
Aug 7, 2025
Q1
2025
Mar 31, 2025
$7.68M
May 5, 2025
Q3
2025
Sep 30, 2024
$0
Nov 6, 2025
Q2
2025
Jun 30, 2024
$0
Aug 7, 2025
Q1
2025
Mar 31, 2024
$10.01M
May 5, 2025
Q3
2024
Sep 30, 2023
$25.20M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$119.0K
Aug 6, 2024
Q1
2024
Mar 31, 2023
$226.0K
May 2, 2024
Q3
2023
Sep 30, 2022
$344.0K
Nov 2, 2023
Q2
2023
Jun 30, 2022
$365.0K
Aug 8, 2023
Q1
2023
Mar 31, 2022
$419.0K
May 4, 2023
Q3
2022
Sep 30, 2021
$666.0K
Nov 3, 2022
Q2
2022
Jun 30, 2021
$844.0K
Aug 4, 2022
Q1
2022
Mar 31, 2021
$952.0K
May 5, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($74.15M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($70.38M)
Aug 7, 2025
Q3
2025
Jun 30, 2025
($70.38M)
Nov 6, 2025
Q3
2025
Mar 31, 2025
($77.07M)
Nov 6, 2025
Q2
2025
Mar 31, 2025
($77.07M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($77.07M)
May 5, 2025
Q3
2025
Sep 30, 2024
($88.11M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($92.21M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($92.21M)
Nov 6, 2025
Q1
2025
Mar 31, 2024
($81.39M)
May 5, 2025
Q2
2025
Mar 31, 2024
($81.39M)
Aug 7, 2025
Q3
2025
Mar 31, 2024
($81.39M)
Nov 6, 2025
Q3
2024
Sep 30, 2023
($65.73M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($98.51M)
Aug 6, 2024
Q3
2024
Jun 30, 2023
($98.51M)
Nov 6, 2024
Q3
2024
Mar 31, 2023
($94.24M)
Nov 6, 2024
Q2
2024
Mar 31, 2023
($94.24M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($94.24M)
May 2, 2024
Q3
2023
Sep 30, 2022
($84.17M)
Nov 2, 2023
Q3
2023
Jun 30, 2022
($76.79M)
Nov 2, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($80.39M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($76.85M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($84.87M)
May 5, 2025
Q3
2025
Sep 30, 2024
($96.37M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($100.76M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($90.36M)
May 5, 2025
Q3
2024
Sep 30, 2023
($73.58M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($106.05M)
Aug 6, 2024
Q1
2024
Mar 31, 2023
($101.18M)
May 2, 2024
Q3
2023
Sep 30, 2022
($85.89M)
Nov 2, 2023
Q2
2023
Jun 30, 2022
($77.81M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($62.72M)
May 4, 2023
Q3
2022
Sep 30, 2021
($60.99M)
Nov 3, 2022
Q2
2022
Jun 30, 2021
($193.58M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($42.41M)
May 5, 2022
Q3
2021
Sep 30, 2020
($36.61M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($27.72M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($26.46M)
May 13, 2021
Q3
2020
Sep 30, 2019
($21.91M)
Nov 12, 2020
Q2
2020
Jun 30, 2019
($19.91M)
Aug 27, 2020